BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7439177)

  • 1. Properties of amidinated glucagons.
    Wright DE; Rodbell M
    Eur J Biochem; 1980 Oct; 111(1):11-6. PubMed ID: 7439177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of specific trinitrophenylation of the lysine epsilon amino group of glucagon on receptor binding and adenylate cyclase activation.
    Liepnieks JJ; Epand RM
    Arch Biochem Biophys; 1983 Aug; 225(1):102-9. PubMed ID: 6311099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor binding and adenylate cyclase activities of glucagon analogues modified in the N-terminal region.
    McKee RL; Pelton JT; Trivedi D; Johnson DG; Coy DH; Sueiras-Diaz J; Hruby VJ
    Biochemistry; 1986 Apr; 25(7):1650-6. PubMed ID: 3011069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential acid stabilities of citraconylated amino groups of glucagon. Preparation of N alpha-citraconyl glucagon and evaluation of its biological properties.
    Liepnieks JJ; Epand RM
    Biochim Biophys Acta; 1982 Oct; 707(2):171-7. PubMed ID: 6291617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of 2-thioltryptophan-glucagon and (tryptophan-S-glucagon)2. Differences in binding to the glucagon receptor in the hepatic adenylate cyclase system.
    Wright DE; Rodbell M
    J Biol Chem; 1980 Nov; 255(22):10884-7. PubMed ID: 7430160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semisynthetic derivatives of glucagon. The contribution of histidine-1 to hormone conformation and activity.
    Flanders KC; Horwitz EM; Gurd RS
    J Biol Chem; 1984 Jun; 259(11):7031-7. PubMed ID: 6547139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of nonspecific hydrophobic interactions in the biological activity of N epsilon-acyl derivatives of glucagon. Studies of conformation, receptor binding, and adenylate cyclase activation.
    Carrey EA; Epand RM
    J Biol Chem; 1982 Sep; 257(18):10624-30. PubMed ID: 6286664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver. Study of chemically modified forms of the hormone, including N alpha-trinitrophenyl glucagon, an antagonist.
    Epand RM; Rosselin G; Hoa DH; Cote TE; Laburthe M
    J Biol Chem; 1981 Feb; 256(3):1128-32. PubMed ID: 6256384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N alpha-Malto-glucagon and N alpha-malto, S-methyl methionine27-glucagon: preparation and characterization of two partial agonists.
    Coolican SA; Gurd RS
    Arch Biochem Biophys; 1984 Aug; 232(2):450-7. PubMed ID: 6380408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semisynthetic derivatives of glucagon: (des-His1)N epsilon-acetimidoglucagon and N alpha-Biotinyl-N epsilon-acetimidoglucagon.
    Flanders KC; Mar DH; Folz RJ; England RD; Coolican SA; Harris DE; Floyd AD; Gurd RS
    Biochemistry; 1982 Aug; 21(18):4244-51. PubMed ID: 7126542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives.
    Heithier H; Ward LD; Cantrill RC; Klein HW; Im MJ; Pollak G; Freeman B; Schiltz E; Peters R; Helmreich EJ
    Biochim Biophys Acta; 1988 Oct; 971(3):298-306. PubMed ID: 2844291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon.
    Lin MC; Wright DE; Hruby VJ; Rodbell M
    Biochemistry; 1975 Apr; 14(8):1559-63. PubMed ID: 164891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photoaffinity labeling of the glucagon receptor with a new glucagon analog.
    Wright DE; Horuk R; Rodbell M
    Eur J Biochem; 1984 May; 141(1):63-7. PubMed ID: 6327311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon: structure-function relationships investigated by sequence deletions.
    Frandsen EK; Grønvald FC; Heding LG; Johansen NL; Lundt BF; Moody AJ; Markussen J; Vølund A
    Hoppe Seylers Z Physiol Chem; 1981 Jun; 362(6):665-77. PubMed ID: 6268519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon amino groups. Evaluation of modifications leading to antagonism and agonism.
    Bregman MD; Trivedi D; Hruby VJ
    J Biol Chem; 1980 Dec; 255(24):11725-31. PubMed ID: 7440567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylglucagon: preparation and characterization.
    Desbuguois B
    Eur J Biochem; 1975 Dec; 60(2):335-47. PubMed ID: 1270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase.
    Krstenansky JL; Trivedi D; Hruby VJ
    Biochemistry; 1986 Jul; 25(13):3833-9. PubMed ID: 3017406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.